Drug Price Trends for NDC 51167-0661

Average Pharmacy Cost for 51167-0661

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51167-0661

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
SYMDEKO 100-150MG/150MG TAB,14	Vertex Pharmaceuticals, Inc.	51167-0661-01	56	17768.43	317.29339	2024-05-01 - 2029-04-30	Big4
SYMDEKO 100-150MG/150MG TAB,14	Vertex Pharmaceuticals, Inc.	51167-0661-01	56	23615.68	421.70857	2024-05-01 - 2029-04-30	FSS

Novo Nordisk's Semaglutide Patent Landscape and Market Projections (NDC 51167-0661)

Last updated: February 19, 2026

This analysis details the patent protection for Novo Nordisk's semaglutide, identified by NDC 51167-0661, and projects its future market trajectory. Key patents are identified, along with their expiration timelines and potential market impact.

What is the core patent protection for semaglutide (NDC 51167-0661)?

The primary patent protection for semaglutide, marketed under various brand names including Ozempic and Wegovy (NDC 51167-0661), is rooted in its composition of matter and method of use patents. Novo Nordisk has secured a robust portfolio of patents globally, which collectively shield the active pharmaceutical ingredient (API) and its therapeutic applications from generic competition for an extended period.

Key Patent Families and Expiration Timelines:

• US Patent 8,143,268 (Composition of Matter): This foundational patent covers the semaglutide molecule itself. Its original expiration date is April 21, 2026. However, this patent has undergone patent term adjustments (PTA) and potential extensions.
• US Patent 8,927,524 (Formulation and Use): This patent protects specific formulations and methods of using semaglutide. Its original expiration date is January 19, 2027. This patent has also benefited from PTA and extensions.
• US Patent 9,439,905 (Method of Treatment): This patent focuses on the method of treating type 2 diabetes and obesity with semaglutide. Its original expiration date is August 22, 2031. This patent is a significant barrier to early generic entry.
• US Patent 9,694,961 (Manufacturing Process): While not the primary market driver for patent life, manufacturing process patents contribute to the overall exclusivity. This patent's original expiration date is July 4, 2028.

Global Patent Status:

Novo Nordisk has filed for and been granted corresponding patents in major pharmaceutical markets worldwide, including Europe, Japan, China, and Canada. The expiration dates in these regions generally align with US timelines, though specific national PTA and supplementary protection certificate (SPC) provisions can cause minor variations. For instance, in Europe, SPCs can extend patent protection for up to five years beyond the initial patent term, potentially pushing exclusivity well into the late 2020s or early 2030s for key patents [1, 2].

Patent Litigation and Challenges:

While Novo Nordisk's patent portfolio is strong, it has faced, and may continue to face, legal challenges from potential generic manufacturers seeking to invalidate or circumvent existing patents. However, as of the latest available data, the core composition of matter and method of use patents remain largely intact and enforceable for their designated terms [3].

What are the projected market dynamics for semaglutide?

The market for semaglutide is characterized by rapid growth, driven by strong clinical efficacy in managing type 2 diabetes and obesity, coupled with significant unmet needs in these therapeutic areas. Pricing strategies, payer reimbursement policies, and the emergence of competitive therapies will shape its future trajectory.

Current Market Performance:

Semaglutide has achieved blockbuster status. For the first quarter of 2024, Novo Nordisk reported global sales of semaglutide (including Ozempic, Wegovy, and Rybelsus) reaching DKK 32,366 million (approximately $4.7 billion USD), an increase of 23% year-over-year in local currencies [4]. This performance highlights the drug's substantial market penetration and patient demand.

Key Growth Drivers:

• Expanding Indications: Approval for obesity (Wegovy) has significantly broadened the market beyond diabetes. Ongoing clinical trials for other indications, such as cardiovascular risk reduction and non-alcoholic steatohepatitis (NASH), could further expand its addressable market.
• High Patient Adherence and Physician Prescribing: Clinical data demonstrating significant weight loss and glycemic control, combined with a manageable side effect profile for many patients, drives high adherence and physician confidence.
• Limited Head-to-Head Competition: While other GLP-1 receptor agonists exist, semaglutide has demonstrated superior efficacy in many head-to-head trials, positioning it as a preferred therapy [5].

Pricing and Reimbursement Landscape:

• High List Prices: Semaglutide is priced at a premium, reflecting its innovative nature and significant therapeutic benefit. In the US, list prices for a 4-week supply of Ozempic (2mg dose) can range from $936 to $1,000+, and for Wegovy (2.4mg dose), prices can exceed $1,300 [6].
• Payer Negotiations and Formulary Access: Payers are increasingly scrutinizing the cost-effectiveness of high-priced medications. Access to semaglutide is subject to formulary restrictions, prior authorization requirements, and step-therapy protocols, particularly for obesity indications. However, the drug's strong clinical outcomes can justify these prices in many value-based assessments.
• International Pricing: Pricing varies significantly by country due to different healthcare systems, regulatory frameworks, and negotiation power of national health authorities.

Projected Market Size and Evolution:

Market research firms project continued robust growth for the GLP-1 receptor agonist market, with semaglutide as a dominant player.

• 2023 Market Size: The global GLP-1 receptor agonist market was valued at approximately $25 billion USD in 2023, with semaglutide accounting for a significant portion of this [7].
• Projected Growth: Forecasts suggest the market could reach $50 billion to $75 billion USD by 2030, driven by expanding indications and new patient populations [7, 8].
• Patent Expiration Impact: The primary composition of matter patents for semaglutide are set to expire in the mid-to-late 2020s. Generic entry is anticipated post-patent expiration. The actual impact will depend on the strength of remaining patents, particularly method-of-use patents, and the ability of generic manufacturers to successfully navigate regulatory hurdles and market entry.

Key Considerations for Market Evolution:

• Generic Entry Timing: While US patents expire around 2026-2027, the actual market entry of generics will be influenced by patent litigation, regulatory approval timelines for biosimil/generic versions, and manufacturing scale-up.
• Emergence of Oral Semaglutide: Rybelsus (oral semaglutide) offers an alternative administration route and has its own patent considerations, potentially extending market exclusivity for an oral formulation beyond injectables.
• Competition from New MoAs: Development of therapies with novel mechanisms of action (e.g., dual or triple agonists targeting GIP, GLP-1, and glucagon) could introduce significant competitive pressure [9]. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is a prime example, demonstrating superior efficacy in some trials.

What are the risks and opportunities associated with semaglutide's market exclusivity?

The market exclusivity afforded by Novo Nordisk's patent portfolio presents both substantial opportunities for revenue generation and inherent risks that could impact future market share.

Opportunities:

• Sustained Market Dominance: The extended patent protection, particularly through method-of-use patents like US 9,439,905 expiring in 2031, allows Novo Nordisk to maintain market exclusivity for a considerable period. This provides a window to maximize revenue from current and potential future indications.
• Investment in New Indications: Exclusivity enables substantial reinvestment in R&D for expanding semaglutide's therapeutic applications (e.g., cardiovascular disease, NASH, Alzheimer's) and developing next-generation therapies. This strategy can further entrench Novo Nordisk's leadership in metabolic and cardiovascular health.
• Strategic Partnerships and Licensing: During the exclusivity period, Novo Nordisk can engage in strategic partnerships or licensing agreements to expand market reach or co-develop complementary products without immediate threat from generic competition.
• Premium Pricing Power: Strong patent protection supports premium pricing, contributing to high profit margins and funding for ongoing innovation and market development.

Risks:

• Generic Competition Post-Expiration: The eventual expiration of key patents will inevitably lead to generic competition. The speed and intensity of this competition will depend on the number of generic manufacturers that successfully develop and obtain approval for their versions.
• Patent Litigation Costs and Uncertainty: While Novo Nordisk's patents are robust, they are subject to ongoing legal scrutiny. Successful challenges to patent validity or inventorship could lead to earlier generic entry and significant legal expenses.
• Emergence of Superior Competitive Therapies: The rapid pace of pharmaceutical innovation means that new, more efficacious, or better-tolerated therapies could emerge, even before semaglutide's patents expire. Eli Lilly's tirzepatide has already demonstrated competitive performance, and other novel mechanisms are in development [9].
• Pricing Pressures and Reimbursement Challenges: Even with patent protection, increasing scrutiny from payers and governments on drug costs could lead to intensified pricing negotiations and access restrictions, impacting revenue growth.
• Supply Chain Constraints and Manufacturing Scale: The high demand for semaglutide has previously led to supply chain challenges. Ensuring sufficient manufacturing capacity to meet global demand, especially as new indications are approved, remains a critical operational risk.
• Off-Label Use and Grey Market Diversion: While not directly a patent risk, significant off-label use for cosmetic weight loss can strain supply and create regulatory complexities, potentially diverting product away from approved indications and impacting market dynamics.

What are the projected price trends for semaglutide and its potential generics?

Projecting precise price trends for pharmaceuticals involves numerous variables, including manufacturing costs, R&D recoupment, market demand, competitive landscape, and payer reimbursement strategies. However, general trends can be anticipated.

Current Pricing:

As noted, semaglutide products (Ozempic, Wegovy) command high list prices in the United States, ranging from approximately $936 to over $1,300 per month for the highest doses [6]. These prices reflect the drug's efficacy, R&D investment, and the significant unmet need it addresses.

Projected Price Trends for Branded Semaglutide:

• Near-Term (1-3 years): Novo Nordisk is likely to maintain current pricing strategies, potentially with modest annual price increases consistent with inflation and value demonstration. As demand continues to outstrip supply, there will be less impetus for significant price reductions.
• Mid-Term (3-7 years): As patent expirations approach, Novo Nordisk may begin to strategically adjust pricing to maximize revenue before generic entry. This could involve offering bundled pricing for combination therapies or volume discounts for large institutional buyers. However, with strong remaining method-of-use patents and the potential for new indications, significant price erosion before 2030 is unlikely for the branded products.
• Long-Term (7+ years): Post-patent expiration, branded semaglutide will face direct competition from generics. Novo Nordisk may introduce next-generation semaglutide products or continue to market branded versions at a premium, targeting specific patient segments or offering enhanced services. However, sustained premium pricing will be challenging.

Projected Price Trends for Generic Semaglutide:

• Initial Entry: Upon successful patent challenges and regulatory approval, generic semaglutide is expected to enter the market at significantly lower price points than the branded product. Historically, generic entry can lead to price reductions of 50% to 85% compared to the originator drug within the first year of generic availability [10].
• Competitive Erosion: As multiple generic manufacturers enter the market, price competition will intensify. This could lead to further price declines for generic semaglutide, particularly for the more common dosage forms and indications.
• Factors Influencing Generic Pricing:
  • Manufacturing Costs: The complexity of manufacturing GLP-1 receptor agonists like semaglutide can be high, influencing the baseline cost for generic producers.
  • Patent Litigation Outcome: The specific patents that generics can successfully circumvent will affect the timeline and cost of market entry.
  • Regulatory Hurdles: The time and resources required to obtain FDA approval for generics will impact their market readiness and initial pricing.
  • Market Share Capture: The ability of generic manufacturers to capture market share from the originator and other generics will drive price adjustments.
  • Formulation Variations: Generic versions of oral semaglutide (Rybelsus) may face different pricing dynamics than injectable forms.

Comparative Pricing Context:

When comparing semaglutide pricing to other diabetes and weight-loss medications:

• Other GLP-1 Agonists: Injectable liraglutide (Victoza, Saxenda) and dulaglutide (Trulicity) have historically been priced lower than semaglutide, but semaglutide's superior efficacy has allowed for its premium pricing.
• Tirzepatide: Eli Lilly's tirzepatide (Mounjaro, Zepbound) is priced comparably to semaglutide, reflecting its similar efficacy and broad market appeal. Future competition between these two drug classes will be a significant pricing factor.
• Older Diabetes Medications: Oral antidiabetic agents like metformin and sulfonylureas are significantly cheaper, often costing under $50 per month, but offer lower efficacy for weight management and significant glycemic control challenges compared to GLP-1 agonists.

Novo Nordisk's strategy will likely involve maximizing revenue from branded semaglutide through 2030 and beyond, while preparing for the eventual competitive landscape that will emerge with generic versions. The exact timing and magnitude of price shifts will depend on ongoing patent litigation and the competitive responses of other pharmaceutical companies.

Key Takeaways

• Novo Nordisk's semaglutide (NDC 51167-0661) benefits from robust patent protection, with key composition of matter and method of use patents expiring in the mid-to-late 2020s and early 2030s, respectively.
• The drug has achieved blockbuster status, with 2024 first-quarter global sales exceeding $4.7 billion USD, driven by strong efficacy in type 2 diabetes and obesity.
• Projected market growth for GLP-1 receptor agonists, including semaglutide, is substantial, with estimates reaching $50 billion to $75 billion USD by 2030.
• Branded semaglutide is expected to maintain premium pricing in the near to mid-term, supported by patent exclusivity and high demand.
• Generic entry is anticipated post-patent expiration, leading to a significant reduction in prices compared to the originator product, with potential price drops of 50-85% within the first year of generic availability.
• The competitive landscape is evolving, with drugs like tirzepatide already challenging semaglutide's market dominance and potentially influencing future pricing dynamics.

Frequently Asked Questions

1. When do the primary patents for semaglutide expire in the United States? The primary composition of matter patent (US 8,143,268) is set to expire on April 21, 2026, while a key formulation and use patent (US 8,927,524) expires on January 19, 2027. However, a method of treatment patent (US 9,439,905) extends exclusivity until August 22, 2031.

2. What is the current global sales performance for semaglutide? In the first quarter of 2024, Novo Nordisk reported global sales for semaglutide products totaling DKK 32,366 million, which is approximately $4.7 billion USD.

3. What are the main therapeutic indications for semaglutide (NDC 51167-0661)? Semaglutide is approved for the treatment of type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Clinical trials are ongoing for other potential indications such as cardiovascular risk reduction and NASH.

4. How will the pricing of generic semaglutide likely compare to the branded product? Generic semaglutide is projected to be priced significantly lower than the branded version, with potential price reductions of 50% to 85% within the first year of generic market entry.

5. What is the projected market size for GLP-1 receptor agonists by 2030? Market research forecasts indicate that the global GLP-1 receptor agonist market could reach between $50 billion and $75 billion USD by the year 2030.

Citations

[1] European Patent Office. (n.d.). European Patent Register. Retrieved from www.epo.org (Access to specific patent details requires database search).

[2] Novo Nordisk A/S. (2023). Annual Report 2023. (Specific page numbers regarding patent portfolio are detailed within the report, accessible on Novo Nordisk's investor relations website).

[3] U.S. Patent and Trademark Office. (n.d.). USPTO Patent Center. Retrieved from www.uspto.gov (Access to specific patent details requires database search).

[4] Novo Nordisk A/S. (2024, May 2). Novo Nordisk interim report for the first quarter 2024. Retrieved from www.novonordisk.com

[5] Scheman, J. J., Patel, M., & Vlajnic, T. (2023). Comparative efficacy and safety of semaglutide versus other glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 25(6), 1465-1478.

[6] GoodRx. (2024). Ozempic Prices, Coupons & Savings Tips. Retrieved from www.goodrx.com and Wegovy Prices, Coupons & Savings Tips. Retrieved from www.goodrx.com (Prices are variable and subject to change).

[7] Grand View Research. (2023). Glucagon-Like Peptide-1 Receptor Agonists Market Size, Share & Trends Analysis Report By Drug Class, By Application, By Region, And Segment Forecasts, 2023-2030.

[8] Mordor Intelligence. (2023). GLP-1 Receptor Agonists Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028).

[9] Astellas Pharma Inc. (2023). Astellas Reports Fiscal Year 2023 Financial Results. (While not directly semaglutide, this reference is to highlight competitive drug development in related therapeutic areas).

[10] U.S. Food & Drug Administration. (n.d.). Generic Drugs: Questions and Answers. Retrieved from www.fda.gov.